Nurix Therapeutics (NRIX) Insider Trading & Ownership $12.15 -0.40 (-3.19%) Closing price 04:00 PM EasternExtended Trading$12.14 -0.01 (-0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Nurix Therapeutics (NASDAQ:NRIX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$2.22 M Get NRIX Insider Trade Alerts Want to know when executives and insiders are buying or selling Nurix Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NRIX Insider Buying and Selling by Quarter Remove Ads Nurix Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/3/2025Houte Hans VanCFOSell5,825$14.49$84,404.25 1/30/2025Gwenn HansenInsiderSell3,690$19.85$73,246.50 1/30/2025Houte Hans VanCFOSell2,811$19.85$55,798.35 11/1/2024Houte Hans VanCFOSell3,546$24.28$86,096.88 10/30/2024Gwenn HansenInsiderSell3,437$24.30$83,519.10 10/30/2024Houte Hans VanCFOSell2,368$24.30$57,542.40 10/14/2024Christine RingInsiderSell3,290$25.00$82,250.00 10/1/2024Christine RingInsiderSell5,760$22.23$128,044.80 9/3/2024Christine RingInsiderSell9,050$24.94$225,707.00 8/26/2024Christine RingInsiderSell9,870$25.01$246,848.70 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/26/2024Houte Hans VanCFOSell20,000$25.22$504,400.00 8/1/2024Christine RingInsiderSell5,760$21.43$123,436.80 8/1/2024Houte Hans VanCFOSell3,477$21.45$74,581.65 7/30/2024Gwenn HansenInsiderSell3,408$20.67$70,443.36 7/30/2024Houte Hans VanCFOSell2,490$20.67$51,468.30 7/1/2024Christine RingInsiderSell5,760$20.81$119,865.60 6/12/2024Christine RingInsiderSell1,900$17.01$32,319.00 6/5/2024Christine RingInsiderSell400$17.00$6,800.00 6/3/2024Christine RingInsiderSell1,596$17.01$27,147.96 5/2/2024Houte Hans VanCFOSell3,499$12.83$44,892.17 4/30/2024Gwenn HansenInsiderSell2,007$12.04$24,164.28 4/30/2024Houte Hans VanCFOSell1,387$12.04$16,699.48 (Data available from 1/1/2013 forward) NRIX Insider Trading Activity - Frequently Asked Questions Who is on Nurix Therapeutics's Insider Roster? The list of insiders at Nurix Therapeutics includes Christine Ring, Gwenn Hansen, Houte Hans Van, and Stefani Wolff. Learn more on insiders at NRIX. What percentage of Nurix Therapeutics stock is owned by insiders? 7.20% of Nurix Therapeutics stock is owned by insiders. Learn more on NRIX's insider holdings. Which Nurix Therapeutics insiders have been selling company stock? The following insiders have sold NRIX shares in the last 24 months: Christine Ring ($1,019,267.42), Gwenn Hansen ($299,426.18), Houte Hans Van ($1,191,304.74), and Stefani Wolff ($3,378.96). How much insider selling is happening at Nurix Therapeutics? Insiders have sold a total of 132,796 Nurix Therapeutics shares in the last 24 months for a total of $2,513,377.30 sold. Nurix Therapeutics Key ExecutivesDr. Arthur T. Sands M.D. (Age 62)Ph.D., CEO, President & Director Compensation: $986.32kMr. Johannes Van Houte (Age 58)Chief Financial Officer Compensation: $681.98kDr. Gwenn M. Hansen Ph.D. (Age 53)Chief Scientific Officer Compensation: $702.75kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardMr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSenior Accounting ManagerDr. Christine Ring J.D. (Age 59)Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer Compensation: $595.83kMr. Eric C. Schlezinger J.D. (Age 57)Chief People Officer Dr. Jason Kantor Ph.D.Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies RNA Insider Trades ACLX Insider Trades OGN Insider Trades ZLAB Insider Trades RARE Insider Trades SWTX Insider Trades AKRO Insider Trades RYTM Insider Trades MRUS Insider Trades CRNX Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:NRIX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech fir...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
